6-KThe Wire
Sanofi files 6-K
Filed Jun 12, 2026 · 21d ago · Accession 0001193125-26-268874
Plain English
Sanofi announced the EU approval of Sarclisa subcutaneous as the first anticancer treatment administered via an on-body injector and provided an update on the MOBILIZE phase 3 study of riliprubart. The company also launched its 2026 global employee stock purchase plan.
Filing details
- Company
- Sanofi
- Ticker
- SNY
- CIK
- 1121404
- Form type
- 6-K
- Filing date
- Jun 12, 2026
- Report date
- Jun 12, 2026
- Document
- d25308d6k.htm
- Size
- 75 KB